Which Companies Will Be Making the News in 2024?

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Getting the latest news at DCAT Week
Kicking off DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing, the DCAT Member Company Announcement Forum is a much-anticipated program in which senior executives from DCAT Member Companies highlight major news from their companies most impactful to the global bio/pharmaceutical manufacturing value chain.

The program is where the industry gathers to hear about the latest manufacturing expansions across all segments: chemicals/chemical active pharmaceutical ingredient (API) manufacturing, biomanufacturing, drug-product manufacturing, and packaging. It is an opportunity to get the details on the capacity being added, when it is coming on line, and the levels of investment behind those expansions.

It is also where the industry comes to get an inside take on the latest in mergers and acquisitions (M&A) from the deal-makers themselves. Senior executives explain their companies’ strategic rationale behind their moves to build critical mass and the details behind those moves: updates on deal closure and post-M&A integration.  

The program is open to all DCAT Member Companies—bio/pharma companies, CDMOs/CMOs, and other suppliers—but companies must apply to be considered for a presentation slot for this prominent event and much sought-after podium time. 

Applications are closing Monday February 5, 2024. The DCAT Member Company Announcement Forum Oversight Committee will then select companies given podium time based on news priority and interest to DCAT Member Companies. A company’s news must be from 2024 and can involve a merger or acquisition, manufacturing expansion, or other major corporate strategic development. Content criteria and online applications can be found here.

Due to popular demand and the number of applications received, this year’s Forum has been expanded and will be held from 9:00 to 11:30 AM on Monday March 18, 2024. Companies of all sizes—large-, medium-, and small-sized companies—may apply to highlight announcements of importance to the industry. But presentation slots are limited, and applications must be received no later than Monday February 5, 2024.

Need examples of past announcements? Check out the companies that made the news at DCAT Week 2023.

Expect a full house and standing room only of DCAT Week’s influential attendees of senior to mid-level executives to be at the program. The DCAT Member Company Announcement Forum will be held at DCAT Week on Monday, March 18, 2024, from 9:00 to 11:30 AM, at the InterContinental Barclay, Grand Ballroom, in New York. Interested in attending? Click here for further information, including how to register to attend.    

Recent Feature Articles

How Autonomous Will the Supply Chain Be?

By
A recent analysis by Gartner projects low uptake of AI for supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations according to the firm’s annual rankings, but how?

Novo at a Crossroads: Will Its Strategic Plan Deliver?

By
Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?

Innovation & Pharma: The Molecules & Companies

By
How truly innovative is the bio/pharma industry? What products, modalities, and companies are behind that innovation? Looking at “first-in-class” new drug approvals, defined as drugs with new mechanisms of action over existing drugs, reveals an interesting picture.

FDA Launches Pilot To Expedite INDs

By
FDA has launched a pilot program to expedite review of investigational new drug (IND) filings with applications for the pilot due by October 30. It is part of the agency’s Operation TrialBlazer initiative, designed to make the US more competitive in early-stage research.